Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. / Heerspink, Hiddo J. L.; Provenzano, Michele; Vart, Priya; Jongs, Niels; Correa-Rotter, Ricardo; Rossing, Peter; Mark, Patrick B.; Pecoits-Filho, Roberto; McMurray, John J. V.; Langkilde, Anna Maria; Wheeler, David C.; Toto, Robert B.; Chertow, Glenn M.

I: American Heart Journal, Bind 270, 2024, s. 125-135.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Heerspink, HJL, Provenzano, M, Vart, P, Jongs, N, Correa-Rotter, R, Rossing, P, Mark, PB, Pecoits-Filho, R, McMurray, JJV, Langkilde, AM, Wheeler, DC, Toto, RB & Chertow, GM 2024, 'Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria', American Heart Journal, bind 270, s. 125-135. https://doi.org/10.1016/j.ahj.2024.02.006

APA

Heerspink, H. J. L., Provenzano, M., Vart, P., Jongs, N., Correa-Rotter, R., Rossing, P., Mark, P. B., Pecoits-Filho, R., McMurray, J. J. V., Langkilde, A. M., Wheeler, D. C., Toto, R. B., & Chertow, G. M. (2024). Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. American Heart Journal, 270, 125-135. https://doi.org/10.1016/j.ahj.2024.02.006

Vancouver

Heerspink HJL, Provenzano M, Vart P, Jongs N, Correa-Rotter R, Rossing P o.a. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. American Heart Journal. 2024;270:125-135. https://doi.org/10.1016/j.ahj.2024.02.006

Author

Heerspink, Hiddo J. L. ; Provenzano, Michele ; Vart, Priya ; Jongs, Niels ; Correa-Rotter, Ricardo ; Rossing, Peter ; Mark, Patrick B. ; Pecoits-Filho, Roberto ; McMurray, John J. V. ; Langkilde, Anna Maria ; Wheeler, David C. ; Toto, Robert B. ; Chertow, Glenn M. / Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. I: American Heart Journal. 2024 ; Bind 270. s. 125-135.

Bibtex

@article{e3b8332a6a474fac9b6069e0b3a01f43,

title = "Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria",

abstract = "BACKGROUND AND AIMS: Sodium-glucose cotransporter 2 inhibitors decrease blood pressure in patients with type 2 diabetes, but the consistency and magnitude of blood pressure lowering with dapagliflozin in patients with chronic kidney disease (CKD) is unknown. We conducted a prespecified analysis of the DAPA-CKD trial to investigate the effect of dapagliflozin on systolic blood pressure (SBP) in patients with CKD, with and without type 2 diabetes.METHODS: A total of 4304 adults with baseline estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m 2 and urinary albumin-to-creatinine ratio (UACR) 200-5000 mg/g were randomized to either dapagliflozin 10 mg or placebo once daily; median follow-up was 2.4 years. The primary endpoint was a composite of sustained ≥50% eGFR decline, end-stage kidney disease, or death from a kidney or cardiovascular cause. Change in SBP was a prespecified outcome. RESULTS: Baseline mean (SD) SBP was 137.1 mmHg (17.4). By Week 2, dapagliflozin compared to placebo reduced SBP by 3.6 mmHg (95% CI 2.8-4.4 mmHg), an effect maintained over the duration of the trial (2.9 mmHg, 2.3-3.6 mmHg). Time-averaged reductions in SBP were 3.2 mmHg (2.5-4.0 mmHg) in patients with diabetes and 2.3 mmHg (1.2-3.4 mmHg) in patients without diabetes. The time-averaged effect of dapagliflozin on diastolic blood pressure (DBP) was 1.0 mmHg (0.6-1.4 mmHg); 0.8 mmHg (0.4-1.3 mmHg) in patients with diabetes and 1.4 mmHg (0.7-2.1 mmHg) in patients without diabetes. Benefits of dapagliflozin on the primary composite and secondary endpoints were evident across the spectrum of baseline SBP and DBP.CONCLUSION: In patients with CKD and albuminuria, randomization to dapagliflozin was associated with modest reductions in systolic and diastolic BP.",

author = "Heerspink, {Hiddo J. L.} and Michele Provenzano and Priya Vart and Niels Jongs and Ricardo Correa-Rotter and Peter Rossing and Mark, {Patrick B.} and Roberto Pecoits-Filho and McMurray, {John J. V.} and Langkilde, {Anna Maria} and Wheeler, {David C.} and Toto, {Robert B.} and Chertow, {Glenn M.}",

year = "2024",

doi = "10.1016/j.ahj.2024.02.006",

language = "English",

volume = "270",

pages = "125--135",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

RIS

TY - JOUR

T1 - Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria

AU - Heerspink, Hiddo J. L.

AU - Provenzano, Michele

AU - Vart, Priya

AU - Jongs, Niels

AU - Correa-Rotter, Ricardo

AU - Rossing, Peter

AU - Mark, Patrick B.

AU - Pecoits-Filho, Roberto

AU - McMurray, John J. V.

AU - Langkilde, Anna Maria

AU - Wheeler, David C.

AU - Toto, Robert B.

AU - Chertow, Glenn M.

PY - 2024

Y1 - 2024

N2 - BACKGROUND AND AIMS: Sodium-glucose cotransporter 2 inhibitors decrease blood pressure in patients with type 2 diabetes, but the consistency and magnitude of blood pressure lowering with dapagliflozin in patients with chronic kidney disease (CKD) is unknown. We conducted a prespecified analysis of the DAPA-CKD trial to investigate the effect of dapagliflozin on systolic blood pressure (SBP) in patients with CKD, with and without type 2 diabetes.METHODS: A total of 4304 adults with baseline estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m 2 and urinary albumin-to-creatinine ratio (UACR) 200-5000 mg/g were randomized to either dapagliflozin 10 mg or placebo once daily; median follow-up was 2.4 years. The primary endpoint was a composite of sustained ≥50% eGFR decline, end-stage kidney disease, or death from a kidney or cardiovascular cause. Change in SBP was a prespecified outcome. RESULTS: Baseline mean (SD) SBP was 137.1 mmHg (17.4). By Week 2, dapagliflozin compared to placebo reduced SBP by 3.6 mmHg (95% CI 2.8-4.4 mmHg), an effect maintained over the duration of the trial (2.9 mmHg, 2.3-3.6 mmHg). Time-averaged reductions in SBP were 3.2 mmHg (2.5-4.0 mmHg) in patients with diabetes and 2.3 mmHg (1.2-3.4 mmHg) in patients without diabetes. The time-averaged effect of dapagliflozin on diastolic blood pressure (DBP) was 1.0 mmHg (0.6-1.4 mmHg); 0.8 mmHg (0.4-1.3 mmHg) in patients with diabetes and 1.4 mmHg (0.7-2.1 mmHg) in patients without diabetes. Benefits of dapagliflozin on the primary composite and secondary endpoints were evident across the spectrum of baseline SBP and DBP.CONCLUSION: In patients with CKD and albuminuria, randomization to dapagliflozin was associated with modest reductions in systolic and diastolic BP.

AB - BACKGROUND AND AIMS: Sodium-glucose cotransporter 2 inhibitors decrease blood pressure in patients with type 2 diabetes, but the consistency and magnitude of blood pressure lowering with dapagliflozin in patients with chronic kidney disease (CKD) is unknown. We conducted a prespecified analysis of the DAPA-CKD trial to investigate the effect of dapagliflozin on systolic blood pressure (SBP) in patients with CKD, with and without type 2 diabetes.METHODS: A total of 4304 adults with baseline estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m 2 and urinary albumin-to-creatinine ratio (UACR) 200-5000 mg/g were randomized to either dapagliflozin 10 mg or placebo once daily; median follow-up was 2.4 years. The primary endpoint was a composite of sustained ≥50% eGFR decline, end-stage kidney disease, or death from a kidney or cardiovascular cause. Change in SBP was a prespecified outcome. RESULTS: Baseline mean (SD) SBP was 137.1 mmHg (17.4). By Week 2, dapagliflozin compared to placebo reduced SBP by 3.6 mmHg (95% CI 2.8-4.4 mmHg), an effect maintained over the duration of the trial (2.9 mmHg, 2.3-3.6 mmHg). Time-averaged reductions in SBP were 3.2 mmHg (2.5-4.0 mmHg) in patients with diabetes and 2.3 mmHg (1.2-3.4 mmHg) in patients without diabetes. The time-averaged effect of dapagliflozin on diastolic blood pressure (DBP) was 1.0 mmHg (0.6-1.4 mmHg); 0.8 mmHg (0.4-1.3 mmHg) in patients with diabetes and 1.4 mmHg (0.7-2.1 mmHg) in patients without diabetes. Benefits of dapagliflozin on the primary composite and secondary endpoints were evident across the spectrum of baseline SBP and DBP.CONCLUSION: In patients with CKD and albuminuria, randomization to dapagliflozin was associated with modest reductions in systolic and diastolic BP.

U2 - 10.1016/j.ahj.2024.02.006

DO - 10.1016/j.ahj.2024.02.006

M3 - Journal article

C2 - 38367893

VL - 270

SP - 125

EP - 135

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -

ID: 385017029